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Résumé 
 
Introduction: Bien que les infections congénitales à cytomégalovirus 
(cCMV) soient la cause non génétique principale de la perte auditive 
neurosensorielle chez l’enfant, leur vrai impact reste inconnu. Objectifs de 
l’étude: 1) Identifier le nombre d’infections cCMV symptomatiques et 
asymptomatiques, diagnostiquées au Centre hospitalier universitaire 
vaudois entre 1999 et 2014; 2) décrire le suivi auditif et 
neurodéveloppemental des enfants avec une infection cCMV; et 3) 
comparer les issues cliniques entre les enfants nés de mères 
primoinfectées versus non-primoinfectées.  
Méthodes: Etude clinique unicentrique, observationelle, descriptive, 
rétrospective de nouveau-nés diagnostiqués d’une infection cCMV au 
Centre hospitalier universitaire vaudois entre 1999 et 2014.  
Résultats: 50 nouveau-nés ont été identifiés avec une infection cCMV; 39 
(78%) étaient symptomatiques à la naissance, dont 29 (74%) avaient des 
symptômes neurologiques. Douze enfants (24%) ont présenté un suivi 
ultérieur auditif et/ou neurodéveloppemental anormal. Des nouveau-nés 
de mères non-primoinfectées étaient plus souvent symptomatiques à la 
naissance, comparés à ceux nés de mères primoinfectées.  
Conclusion: Tous les enfants avec une perte auditive neurosensorielle ou 
un neurodéveloppement anormal étaient symptomatiques à la naissance. 
Des résultats de suivis auditifs et neurodevéloppementaux similaires ont 
été observés chez les enfants nés de mères primoinfectées et non-
primoinfectées.  
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Summary
BACKGROUND: Congenital cytomegalovirus (cCMV) in-
fections are the leading nongenetic cause of congenital
sensorineural hearing loss (SNHL); however the true im-
pact of cCMV infections remains unknown.
AIMS OF THE STUDY: (1) To identify the number of
asymptomatic and symptomatic cCMV infections diag-
nosed between 1999 and 2014 at the Lausanne University
Hospital; (2) to describe the audiological and neurodevel-
opmental outcomes of infants with cCMV infection; and
(3) to compare clinical outcomes between infants born to
mothers with primary versus nonprimary infection.
METHODS: This was a single-centre, observational, ex-
ploratory, retrospective study of newborns diagnosed with
cCMV infection at the Lausanne University Hospital be-
tween 1999 and 2014.
RESULTS: Fifty newborns with cCMV infection were iden-
tified; 39 (78%) were symptomatic at birth, of whom 29
(74%) were neurologically symptomatic. Twelve children
(24%) presented with subsequent abnormal audiological
and/or neurodevelopmental outcomes. Newborns born to
mothers with a nonprimary infection were more often
symptomatic at birth than those born to mothers with a pri-
mary infection.
CONCLUSIONS: All infants with subsequent SNHL or ab-
normal neurodevelopment were symptomatic at birth.
Similar long-term neurodevelopmental and audiological
outcomes were observed in infants born to mothers with a
primary and nonprimary infection.
Key words: congenital CMV infection, sensorineural
hearing loss, neurodevelopment, primary infection, nonpri-
mary infection
Introduction
Congenital cytomegalovirus (cCMV) infections, with a
global estimated prevalence of 0.6 to 0.7%, are the leading
nongenetic cause of congenital sensorineural hearing loss
(SNHL) [1–6]. Cytomegalovirus (CMV) can be transmit-
ted from the mother to the fetus despite pre-existing im-
munity [1–7], from either reactivation or reinfection [6].
Evidence from the literature suggests that infants born to
mothers with primary infection have an equivalent audi-
ological and neurodevelopmental outcome to those born
to mothers with a nonprimary infection [4, 5]. Almost
all newborns with cCMV infections are asymptomatic at
birth. From these asymptomatic neonates, 10 to 15% will
develop neurological sequelae [5]. Overall, 17 to 20% of
all neonates with symptomatic and asymptomatic cCMV
infection will have an abnormal neurological outcome,
mainly SNHL, cognitive delay, neuromotor impairment
such as cerebral palsy and balance disturbances, seizures
or visual impairment [8–10].
Diagnosis of cCMV infection relies on the documentation
of a positive CMV polymerase chain-reaction (PCR) in
urine or saliva during the first 3 weeks of life [11–13].
Whereas some centres have introduced universal neonatal
screening for cCMV [9], others, such as ours, perform tar-
geted neonatal testing [14] in newborns with microcephaly,
subependymal pseudocysts or thrombocytopenia [15–17].
Documentation of cCMV disease in newborns is crucial as
prompt initiation of oral valganciclovir treatment improves
audiological and, possibly, neurodevelopmental outcomes
[16, 18, 19]. Universal screening programmes of newborns
have not been implemented in part because of a lack of epi-
demiological data [20]. As a consequence, asymptomatic
newborns will be diagnosed late through identification of
SNHL [21].
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From recent data, we estimate that cCMV infection could
affect 500 newborns each year in Switzerland, of whom up
to 100 could suffer from lifelong disabilities [9, 22, 23].
We aimed to provide information on neurodevelopmental
and audiological outcomes of newborns with cCMV infec-
tion diagnosed at the Lausanne University Hospital. In ad-
dition, clinical outcomes of infants born to mothers with
primary infection were compared with those born to moth-
ers with nonprimary infection.
Methods
Study design and definitions
This was a single-centre retrospective study of neonates
born between 1999 and 2014 presenting with cCMV in-
fection and treated at the Lausanne University Hospital,
Switzerland. Congenital CMV infection was defined from
1999 to 2004 as a positive CMV viral culture [24], and
from 2005 to 2014 by quantitative measures of viral load
with molecular assays (detection limit 100–1000 copies/
ml [25]) in urine, collected within the first 3 weeks of
life [11–13]. Infants born during the study period and di-
agnosed retrospectively with CMV PCR testing on stored
dried blood spots (Guthrie cards) were also included [26].
Indications for neonatal CMV testing included document-
ed maternal seroconversion during pregnancy, abnormal
prenatal ultrasounds, documentation of CMV by molecular
assays from amniotic fluid (detection limit 100–1000
copies/ml) and postnatal indications such as being small
for gestational age (SGA), microcephaly, subependymal
pseudocysts and/or thrombocytopenia [15–17, 20, 25].
Screening of pregnant women and newborns relied on
physician-based practice and not on predefined screening
policies. Maternal seroconversion during pregnancy was
defined either as documentation of CMV-specific im-
munoglobulins in a patient previously known to be
seronegative, or a newborn with proven cCMV infection
born to a mother without any demonstrable CMV-specific
antibodies during pregnancy [1, 5, 27]. A nonprimary ma-
ternal infection was defined as positive IgM and IgG serol-
ogy with an IgG avidity of ≥70% determined within the
first 12 weeks of pregnancy. The assay used to measure
IgG avidity was an in-house assay based on the Enzygnost
CMV IgG assay (Siemens) using an 8 M urea wash, as de-
scribed elsewhere [28]. The avidity threshold defining re-
mote infection was set using in-house seroconversion pan-
els, and by comparison with the work of Grangeot-Keros
et al. [29].
Symptomatic cCMV infection was defined as one or more
of the following: SGA (birthweight <10th percentile), pe-
techiae, hepatosplenomegaly, elevated conjugated bilirubi-
naemia, thrombocytopenia, elevated transaminases or cen-
tral nervous system involvement [15, 16]. Neurologically
symptomatic cCMV disease referred to one or more of the
following: microcephaly (head circumference <3rd per-
centile), abnormal neurological examination, chorioretini-
tis, SNHL measured with brainstem-evoked response
(BSER) testing, an abnormal brain ultrasound or magnetic
resonance imaging (MRI) scan [16, 18, 30]. An abnormal
brain ultrasound scan was defined by the presence of
periventricular calcifications, white matter hypere-
chogenicities, ventriculomegaly or hydrocephaly.
Subependymal pseudocysts and/or lenticulostriated vascu-
lopathy were considered as nonspecific lesions and were
thus not included in the criteria for an abnormal brain ul-
trasound [5, 17, 19, 31]. An abnormal brain MRI referred
to white matter abnormalities (particularly in temporal, oc-
cipital and parietal white matter), neuronal migration dis-
orders such as schizencephaly, pachygyria, lissencephaly,
polymicrogyria or cortical dysplasia, and cerebellar hy-
poplasia, periventricular calcifications and ventricu-
lomegaly [32–35].
Treatment options for neurologically symptomatic new-
borns consisted of a 6-week intravenous ganciclovir reg-
imen from 2006 to 2012, 6 weeks of intravenous ganci-
clovir with 6 to 12 additional months of oral valganciclovir
in 2013, or 6 to 12 months oral valganciclovir thereafter
[16, 18, 19, 36].
Collection of clinical information, audiological and
neurodevelopmental assessments
Retrospective chart review and use of the database from
the neonatology clinic follow-up unit provided information
on relevant baseline characteristics and outcomes. This
study was approved by the ethics committee on research
involving humans of the canton of Vaud (protocol number
426/14).
Audiological assessment
BSER was assessed at birth and between 3 and 24 months
by an ear-nose-throat (ENT) specialist. Hearing thresholds
were defined as follows: 0 to 30 dB for normal hearing, 31
to 45 dB for mild hearing loss, 46 to 70 dB for moderate
hearing loss and above 71 dB for severe hearing loss [16,
18]. We used total and best ear analyses as described [18].
Audiological outcomes were adjudicated on the latest
BSER.
Neurodevelopmental assessments
Neurodevelopmental follow-up was offered to neurologi-
cally symptomatic patients from 2001. Infants were exam-
ined with the revised Griffiths Mental Development Scales
(GMDS) at 6 months of age [37], and the Bayley Scales
of Infant and Toddler Development second and third edi-
tions (Bayley-II and III) at 12 months and 18 months of
age [38]. Older infants were tested with the Kaufman As-
sessment Battery for Children (K-ABC) first edition [39],
or with the Wechsler Preschool and Primary Scale of Intel-
ligence (WPPSI-R) [40]. Neurodevelopmental outcomes
were based on the latest scores determined with the
GMDS, Bayley-II and III, WPPSI-R, K-ABC, all with an
expected mean of 100 and a standard deviation of 15 with-
in the normal population [37–40]. Hence test results were
classified as abnormal if one test component was below 85.
Sequelae were defined as an abnormal audiological and/or
an abnormal neurodevelopmental outcome.
Statistical analysis
Descriptive statistics were used. Z-scores of the growth pa-
rameters weight, height and head circumference of new-
borns were calculated using the Fenton 2013 Growth Cal-
culator for Preterm Infants [41].
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Results
Study population
From 1999 to 2014, 38,423 newborns were born at Lau-
sanne University Hospital of whom 2274 were tested for
CMV in urine samples. Of these 2274, 48 were found pos-
itive by viral culture or PCR. Among the 48 newborns di-
agnosed with cCMV infection, 24 (50%) were tested for
CMV as a result of maternal seroconversion, 21 (44%) be-
cause they were SGA, 2 (4%) because of thrombocytope-
nia and 1 (2%) as a result of abnormal antenatal ultra-
sounds. Two additional patients (twins) with SNHL (and
subependymal pseudocysts on neonatal brain ultrasound)
tested positive by PCR on stored dried blood-spots at the
age of 3.5 years.
Baseline characteristics and clinical outcomes of all
patients at birth
Maternal serology status was available for 46 of 50 (92%)
women; 35 of the 46 (76%) had a primary infection. Of
the 50 newborns with cCMV infection, 18 (36%) were
born prematurely with a median gestational age of 38.6
weeks; 12 (67%) of these were late preterm (34 0/7 to
36 6/7 weeks of gestation) (table 1). Among the 50 new-
borns with cCMV infection, 39 (78%) were symptomatic,
of whom 29 (58%) were neurologically symptomatic and
24 (48%) were SGA. Five (10%) were born with micro-
cephaly and none presented with chorioretinitis. Among
the 45 newborns in whom a brain ultrasound was per-
formed, 12 (27%) were abnormal, mostly with periven-
tricular hyperechogenicity (50%). An MRI was done in
20 (40%), of whom 55% presented abnormal findings, all
white matter abnormalities. Audiological examination was
performed in 40 newborns, of whom 35 (88%) had normal
hearing with regards to best ear analysis (supplementary
table S1 in appendix 1).
Audiological and neurodevelopmental outcomes of all
patients at 3 months of age and onwards
From the 50 infants with a cCMV infection, audiological
assessment (range 3–26 months) performed by the ENT
specialist was available for 29 (58%), 27 (93%) of whom
had normal hearing in the best ear; among the 58 ears as-
sessed, 81% had normal thresholds. Among the 50 new-
borns with cCMV infection, neurodevelopment follow-up
(range 6–72 months) from 2001 to 2015 was available
for 26 (52%) infants born between 2001 and 2014. Of
these 26, 21 (81%) were offered follow-up as a result of
neurologically symptomatic cCMV infection. Of those 26,
6 (23%) patients presented with abnormal neurodevelop-
ment of whom 3 had SNHL (table S2, appendix 1).
Baseline characteristics, audiological and neurodevel-
opmental outcomes of all children with sequelae
Of the 34 infants for whom audiological and/or neurode-
velopmental follow-up was available, 12 (35%) had se-
quelae. Of these 12, 3 (25%) presented with SNHL and
abnormal neurodevelopment, 1 (8%) with SNHL and un-
known neurodevelopment, 5 (42%) with isolated SNHL
and 3 (25%) with an isolated abnormal neurodevelopmen-
tal outcome. All 12 were symptomatic at birth, including
10 (83%) with neurological symptoms. Among the 9 in-
fants with SNHL, 7 (78%) had unilateral, and 2 (22%) bi-
lateral hearing loss (fig. 1 and table 2).
Clinical characteristics at birth, audiological and neu-
rodevelopmental outcomes of all infants born to moth-
ers with a primary compared with those born to moth-
ers with a nonprimary infection
Newborns born to mothers with nonprimary infection were
more often symptomatic and SGA at birth than those born
to mothers with a primary infection. In contrast, petechiae
were more frequent in newborns born to mothers with pri-
mary infection than in newborns born to mothers with a
nonprimary infection. In the two groups, the rates of mi-
crocephaly and abnormal audiological outcome at birth
were similar (table 3).
Results of hearing assessments and neurodevelopmental
outcomes at 3 months of age and onwards were similar
in children born to mothers with a primary infection and
those with a nonprimary infection (table 4).
Discussion
In this first exploratory study to address the burden of
cCMV infections in Switzerland, three important obser-
vations were made: (1) cCMV infections were detected
equally among newborns born to mothers with primary
infection and nonprimary infection; (2) most infants who
presented with SNHL or abnormal neurodevelopment
were neurologically symptomatic at birth; (3) newborns of
Table 1: Baseline characteristics at birth of all newborns with congenital cytomegalovirus infection.
Infected
n = 50
Maternal infection Primary 35/46 (76%)
Nonprimary 11/46 (24%)
Unknown 4
Sex Female 30/50 (60%)
Prematurity <37 weeks 18/50 (36%)
Median gestational age in weeks 38.6 (IQR 36–40)
Mean weight z-score −1.02 (SD 1.06)
Mean height z-score −1.00 (SD 1.07)
Mean head circumference z-score −0.57 (SD 1.10)
Anti-viral treatment* Yes 13/50 (26%)
No 37/50 (74%)
IQR = interquartile range; SD = standard deviation * Intravenous ganciclovir or oral valganciclovir
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mothers with a primary infection had similar audiological
and neurodevelopmental outcomes as those born to moth-
ers with a nonprimary infection.
We documented a higher proportion of infants born to
mothers with a primary infection (76%) versus nonprimary
infection, compared with a previous report of countries
with a low seroprevalence, like Switzerland (44%) [5].
This finding most likely resulted from the systematic test-
ing for CMV among newborns born to mothers with se-
roconversion at our centre. We report a lower proportion
of symptoms among symptomatic newborns with cCMV
infection compared with others studies [15, 16], whereas
our proportion of neurological symptoms among sympto-
matic newborns was similar. These discrepancies could re-
sult from a less rigorous assessment of clinical and labora-
tory outcomes than of neurological outcomes in our setting
compared with other studies [15, 16]. Careful clinical and
laboratory assessment is warranted in all newborns with
Figure 1: Clinical characteristics at birth and audiological and neurodevelopmental outcomes.
Table 2: Baseline characteristics, audiological and neurodevelopmental outcomes of children with sequelae.
Patient
number
Comorbidities and social difficulties Gestational age
(weeks and days)
Weight
z-score
Height
z-score
Head circum-
ference
z-score
Maternal
primary in-
fection
Neurodevelopmental
outcome
Hearing
loss
1 No 40 1/7 0.04 −1.13 −1.29 Yes Language delay Moderate
right
2 No 37 3/7 0.86 0.4 0.54 Yes Language delay No
3 No 39 1/7 −1.31 −1.04 −1.1 No Normal Moderate
right
4 Maternal HIV infection; difficult psychosocial situa-
tion
38 2/7 −1.57 −1.1 −0.07 No Global delay No
5 Very preterm 28 3/7 −2.05 −3.01 −3.56 Unknown Global delay Moderate
right
6 Chronic maternal hepatitis B infection 38 1/7 −1.87 −0.3 −0.47 No Unknown Severe left
7 Late preterm 36 0/7 −0.06 0.27 0.16 Yes Normal Severe
right, mild
left
8 Late preterm 36 0/7 −0.29 −0.55 −0.17 Yes Normal Severe bi-
lateral
9 No 38 0/7 −2.72 −2.3 −2.16 Yes Normal Severe, left
10 No 41 5/7 −2.75 −2.25 −2.64 Yes Normal Severe,
right
11 Moderate preterm 33 0/7 −2.4 −2.5 −1.18 Unknown Global delay Normal
12 Late preterm 34 6/7 −1,54 −0.33 −1.21 No Motor delay and visu-
al problems
Moderate
left
HIV = human immunodeficiency virus Very preterm = 28 0/7 to 31 6/7, moderate preterm = 32 0/7 to 33 6/7, late preterm = 34 0/7 to 36 6/7 weeks of gestation
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cCMV infection, as petechiae and SGA, as well as throm-
bocytopenia, were identified as significant predictors of
subsequent SNHL [42].
Our study reported a similar rate of SNHL or abnormal
neurodevelopmental outcomes at 3 months of age and on-
wards compared with other studies (24% vs 17–20%) [9].
All our children with subsequent SNHL or abnormal neu-
rodevelopmental scores were symptomatic at birth, in con-
trast to a systematic review [9] that reported that only
one third of children with subsequent SNHL or abnormal
neurodevelopmental outcomes were symptomatic at birth.
As supported by the systematic review [9], neurodevelop-
mental and audiological follow-up should be offered to all
children with cCMV infection identified through universal
newborn screening [9, 43].
Confirming findings of prior reports [4, 7], our study indi-
cated that infants born to mothers with a nonprimary infec-
tion are at least as often symptomatic at birth as those born
to mothers with a primary infection. As documented in oth-
er studies [4, 7], we report equivalent rates of abnormal au-
diological and neurodevelopmental outcomes of children
born to mothers with a primary infection compared with
those born to mothers with a nonprimary infection.
Table 3: Clinical characteristics at birth categorised by newborns born to mothers with primary versus nonprimary infection.
Maternal primary infection
n = 35
Maternal
nonprimary infection
n = 11
Symptomatic 25/35 (71%) 10/11 (91%)
Neurologically symptomatic 18/35 (51%) 8/11 (73%)
SGA 12/35 (34%) 9/11 (82%)
Petechiae 12/35 (34%) 1/11 (9%)
Thrombocytes
Abnormal: <150 G/l
Abnormal 9/26 (35%) 6/11 (55%)
Normal 17/26 (65%) 5/11 (45%)
Unknown 9 0
Microcephaly 3/35 (9%) 1/11 (9%)
Fundus Abnormal 0/31 (0%) 0/9 (0%)
Normal 26/31 (100%) 9/9 (100%)
Unknown 9 2
Brain ultrasound Abnormal 7/31 (23%) 4/10 (40%)
Normal 24/31 (77%) 6/10 (60%)
Unknown 4 1
MRI Abnormal 5/11 (45%) 5/8 (63%)
Normal 6/11 (55%) 3/8 (38%)
Unknown 24 3
BSER best ear Normal 25/28 (89%) 8/10 (80%)
Mild 0/28 (0%) 2/10 (20%)
Moderate 2/28 (7%) 0/10 (0%)
Severe 1/28 (4%) 0/10 (0%)
Unknown 7 1
BSER total ears Normal 45/56 (80%) 15/20 (75%)
Mild 3/56 (5%) 2/20 (10%)
Moderate 5/56 (9%) 3/20 (15%)
Severe 3/56 (5%) 0/20 (0%)
Unknown 14 2
BSER = brain stem evoked response; MRI = magnetic resonance imaging; SGA = small for gestational age
Table 4: Audiological and neurodevelopmental outcome at 3 months of age and onwards, categorised by newborns born to mothers with a primary versus a nonprimary infec-
tion.
Maternal primary infection
n = 35
Maternal nonprimary infection
n = 11
Latest BSER
≥3 months
best ear
Normal 16/18 (89%) 9/9 (100%)
Mild 1/18 (6%) 0/9 (0%)
Moderate 0/18 (0%) 0/9 (0%)
Severe 1/18 (6%) 0/9 (0%)
Unknown 17 2
Latest BSER
≥3 months
total ears
Normal 29/36 (81%) 15/18 (83%)
Mild 1/36 (3%) 0/18 (0%)
Moderate 1/36 (3%) 2/18 (11%)
Severe 5/36 (14%) 1/18 (6%)
Unknown 34 4
Neurodevelopment score ≥6 months Abnormal 2/14 (14%) 2/8 (25%)
Normal 12/14 (86%) 6/8 (75%)
Unknown 21 3
BSER = brain stem evoked response
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Our exploratory study represents an important first step in
reporting audiological and neurodevelopmental outcomes
of newborns with cCMV infection in Switzerland. An im-
portant strength relates to the precise documentation of
BSER measures, including best ears analysis and total ears
analysis, as well as the use of standardised developmental
tests [16]. Limitations of our study include the retrospec-
tive design, inhomogeneous timeframe of the audiological
follow-up and the absence of follow-up of asymptomatic
newborns, which may have biased our findings towards
more severe outcomes among symptomatic children with
longer follow-up. This limitation is inherent to all retro-
spective studies on cCMV infections conducted before the
establishment of recent guidelines on auditory outcomes
measures [3], as reflected in a recent European surveillance
study [44]. However, at each visit at the neurodevelopmen-
tal clinic, hearing was examined by the paediatrician and
those with any abnormal findings were systematically re-
ferred to the ENT specialist. Therefore, we believe that
the wide timeframe of auditory assessment conducted by
the ENT specialist minimally affected our findings. Other
shortcomings of our study relate to the small sample size
inherent to monocentric retrospective studies conducted in
a country with a low prevalence of cCMV infection [5]. In
addition, the absence of universal screening of newborns
may have biased our study towards selecting mothers with
a primary infection and mostly symptomatic newborns,
who presented mostly with normal BSER and neurodevel-
opmental scores.
In conclusion, our study supports current findings on the
burden and severity of cCMV infections [4, 7, 9] and pro-
vides national data on outcomes of newborns with cCMV
infection. Combined information on clinical outcomes
from the current study and epidemiological data provided
by the Swiss Paediatric Surveillance Study (SPSU) will
hopefully encourage the establishment of a national reg-
istry, which will in turn serve as foundation for future
prospective studies.
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Appendix 1 Supplementary tables
Table S1: Clinical outcomes at birth of all newborns with congenital cytomegalovirus infection.
Infected
n = 50
Symptomatic 39/50 (78%)
Neurologically symptomatic 29/50 (58%)
SGA 24/50 (48%)
Petechiae 13/50 (26%)
Thrombocytes
Abnormal: <150 G/l
Abnormal 17/41 (41%)
Normal 24/41 (59%)
Unknown 9
Microcephaly 5/50 (10%)
Fundus Abnormal 0/39 (0%)
Normal 39/39 (100%)
Unknown 11
Brain ultrasound Abnormal 12/45 (27%)
Normal 33/45 (73%)
Unknown 5
MRI Abnormal 11/20 (55%)
Normal 9/20 (45%)
Unknown 30
BSER best ear Normal 35/40 (88%)
Mild 2/40 (5%)
Moderate 2/40 (5%)
Severe 1/40 (3%)
Unknown 10
BSER total ears Normal 64/80 (80%)
Mild 5/80 (6%)
Moderate 8/80 (10%)
Severe 3/80 (4%)
Unknown 20
BSER = brain stem evoked response; MRI = magnetic resonance imaging; SGA = small for gestational age
Table S2: Audiological and neurodevelopmental outcome at 3 months of age and onwards of all newborns with congenital cytomegalovirus infection.
Infected
n = 50
Latest BSER
≥3 months
best ear
Normal 27/29 (93%)
Mild 1/29 (3%)
Moderate 0/29 (0%)
Severe 1/29 (3%)
Unknown 21
Latest BSER
≥3 months
total ears
Normal 47/58 (81%)
Mild 1/58 (2%)
Moderate 4/58 (7%)
Severe 6/58 (10%)
Unknown 42
Neurodevelopment score ≥6 months Abnormal 6/26 (23%)
Normal 20/26 (77%)
Unknown 24
BSER = brain stem evoked response
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Erratum | Published 03 April 2019 | doi:10.4414/smw.2019.20075
Cite this as: Swiss Med Wkly. 2019;149:w20075
Erratum
Correction to: Kobas M, et al. Clinical characteristics, au-
diological and neurodevelopmental outcomes of newborns
with congenital cytomegalovirus infection. Swiss Med Wk-
ly. 2018;148:w14627.
In the methods section, there was an error in the following
sentence: “Screening of pregnant woman and newborns re-
lied on physician-based practice and on predefined screen-
ing policies.”
The correct text should be: “Screening of pregnant woman
and newborns relied on physician-based practice and not
on predefined screening policies.”
The online version of the article has been corrected accord-
ingly.
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